Posts Tagged ‘myelofibrosis’

Ruxolitinib for Myelofibrosis

Posted by Sara Fazio • March 2nd, 2012

A new trial from Verstovsek and others showed clinically significant responses in spleen size and quality of life among patients with myelofibrosis receiving the ruxolitinib, a JAK1 and JAK2 inhibitor. The agent has some myelotoxicity, but this study showed a survival advantage with ruxolitinib. Myelofibrosis, a myeloproliferative neoplasm, is manifested by abnormal blood counts (anemia, thrombocytosis… Read More…

Posted in Physicians-In-Training | Permalink | No Comments

In Myelofibrosis, Relief with Halting the Cytokine Storm

Posted by Ishani Ganguli • February 29th, 2012

An older patient comes to you with severe night sweats, debilitating fatigue, abdominal pain, weight loss, and itching. High on your differential is myelofibrosis, the proliferative blood disorder that scars the bone marrow, causing abnormal blood counts and a spleen swollen with the effort of producing blood cells. We think the disease stems from dysregulation… Read More…

Posted in Insights | Permalink | No Comments